In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors

Coskuner E., Cevik I., Ozkan A., DİLLİOĞLUGİL Ö., Akdas A.

INTERNATIONAL UROLOGY AND NEPHROLOGY, vol.44, no.3, pp.793-798, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 44 Issue: 3
  • Publication Date: 2012
  • Doi Number: 10.1007/s11255-012-0144-x
  • Journal Name: INTERNATIONAL UROLOGY AND NEPHROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.793-798
  • Keywords: NMP22, Urine marker, Bladder cancer, Upper urinary tract tumor, TCC, SUPERFICIAL BLADDER-CANCER, NUCLEAR-MATRIX PROTEIN, CARE PROTEOMIC ASSAY, UROTHELIAL CANCER, NATURAL-HISTORY, RENAL PELVIS, RISK-FACTORS, IN-SITU, SURVEILLANCE, CYTOLOGY
  • Kocaeli University Affiliated: Yes

Abstract

Two percent of the bladder non-muscle-invasive (NMI) transitional cell carcinomas (TCC) are associated with upper urinary tract (UUT) TCC. We evaluated the role of nuclear matrix protein-22 (NMP-22) (BladderChek(A (R))) test in the diagnosis of lower urinary tract and UUT-TCC.